Cellectar Biosciences, Inc. Logo

Cellectar Biosciences, Inc.

Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.

CLRB | US

Overview

Corporate Details

ISIN(s):
US15117F8077
LEI:
Country:
United States of America
Address:
100 CAMPUS DRIVE, 7932 FLORHAM PARK

Description

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cellectar Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellectar Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellectar Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops drug delivery technology for localized chemotherapy in solid tumors.
Virgin Islands (British)
CRTX
CRISPR Therapeutics AG Logo
A gene-editing company developing gene-based medicines for serious diseases.
United States of America
CRSP
Crossject Logo
Develops emergency medications delivered via a needle-free auto-injector platform.
France
ALCJ
CSL Ltd. Logo
Global biotechnology company developing biotherapies, vaccines, and specialty medicines.
Australia
CSL
CS Medica A/S Logo
Develops and manufactures OTC medical devices and cosmetics containing cannabidiol.
Denmark
CSMED
CTC BIO, INC. Logo
Develops and manufactures human and animal health products using microbial fermentation.
South Korea
060590
Cue Biopharma, Inc. Logo
Develops biologics to selectively modulate the immune system for cancer and autoimmune diseases.
United States of America
CUE
Cullinan Therapeutics, Inc. Logo
A clinical-stage biopharmaceutical company developing therapies for cancer and autoimmune diseases.
United States of America
CGEM
CUMBERLAND PHARMACEUTICALS INC Logo
Acquires, develops, and commercializes branded drugs for hospital and acute care.
United States of America
CPIX
Cuorips Inc. Logo
Develops iPS cell-derived therapies and provides cell processing contract services.
Japan
4894

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.